Arrivent Biopharma, Common Stock Price Prediction
| AVBP Stock | 27.45 0.86 3.23% |
Oversold Vs Overbought
65
Oversold | Overbought |
Using ArriVent BioPharma, hype-based prediction, you can estimate the value of ArriVent BioPharma, Common from the perspective of ArriVent BioPharma, response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in ArriVent BioPharma, to buy its stock at a price that has no basis in reality. In that case, they are not buying ArriVent because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
ArriVent BioPharma, after-hype prediction price | USD 27.45 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
ArriVent |
ArriVent BioPharma, After-Hype Price Prediction Density Analysis
As far as predicting the price of ArriVent BioPharma, at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in ArriVent BioPharma, or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of ArriVent BioPharma,, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
ArriVent BioPharma, Estimiated After-Hype Price Volatility
In the context of predicting ArriVent BioPharma,'s stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on ArriVent BioPharma,'s historical news coverage. ArriVent BioPharma,'s after-hype downside and upside margins for the prediction period are 23.77 and 31.13, respectively. We have considered ArriVent BioPharma,'s daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
ArriVent BioPharma, is not too volatile at this time. Analysis and calculation of next after-hype price of ArriVent BioPharma, is based on 3 months time horizon.
ArriVent BioPharma, Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as ArriVent BioPharma, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ArriVent BioPharma, backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with ArriVent BioPharma,, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.05 | 3.68 | 0.00 | 0.07 | 0 Events / Month | 5 Events / Month | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
27.45 | 27.45 | 0.00 |
|
ArriVent BioPharma, Hype Timeline
ArriVent BioPharma, is presently traded for 27.45. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.07. ArriVent is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is presently at 0.05%. %. The volatility of related hype on ArriVent BioPharma, is about 254.04%, with the expected price after the next announcement by competition of 27.52. About 14.0% of the company shares are held by company insiders. The book value of ArriVent BioPharma, was presently reported as 8.85. The company recorded a loss per share of 2.24. ArriVent BioPharma, had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in 5 to 10 days. Check out ArriVent BioPharma, Basic Forecasting Models to cross-verify your projections.ArriVent BioPharma, Related Hype Analysis
Having access to credible news sources related to ArriVent BioPharma,'s direct competition is more important than ever and may enhance your ability to predict ArriVent BioPharma,'s future price movements. Getting to know how ArriVent BioPharma,'s peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how ArriVent BioPharma, may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| TSLA | Tesla Inc | 10.15 | 7 per month | 2.64 | 0.16 | 8.19 | (5.77) | 28.06 | |
| GZITF | Yuexiu Transport Infrastructure | 0.00 | 0 per month | 0.00 | 0.09 | 0.00 | 0.00 | 26.67 | |
| AFYA | Afya | (0.35) | 7 per month | 0.00 | (0.12) | 2.62 | (4.21) | 9.86 | |
| LIND | Lindblad Expeditions Holdings | 0.03 | 8 per month | 2.18 | 0.11 | 4.92 | (3.83) | 29.57 | |
| NXPL | Nextplat Corp | 0.06 | 8 per month | 0.00 | (0.08) | 4.88 | (7.80) | 34.56 | |
| SPHR | Sphere Entertainment Co | 0.26 | 8 per month | 0.00 | (0.13) | 5.06 | (4.40) | 14.27 | |
| BEDU | Bright Scholar Education | (0.01) | 4 per month | 3.20 | (0.01) | 5.56 | (5.85) | 18.70 |
ArriVent BioPharma, Additional Predictive Modules
Most predictive techniques to examine ArriVent price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for ArriVent using various technical indicators. When you analyze ArriVent charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About ArriVent BioPharma, Predictive Indicators
The successful prediction of ArriVent BioPharma, stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as ArriVent BioPharma, Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of ArriVent BioPharma, based on analysis of ArriVent BioPharma, hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to ArriVent BioPharma,'s market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to ArriVent BioPharma,'s related companies.
Story Coverage note for ArriVent BioPharma,
The number of cover stories for ArriVent BioPharma, depends on current market conditions and ArriVent BioPharma,'s risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that ArriVent BioPharma, is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about ArriVent BioPharma,'s long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
ArriVent BioPharma, Short Properties
ArriVent BioPharma,'s future price predictability will typically decrease when ArriVent BioPharma,'s long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of ArriVent BioPharma, Common often depends not only on the future outlook of the potential ArriVent BioPharma,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ArriVent BioPharma,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 32 M | |
| Cash And Short Term Investments | 150.4 M |
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.